Equibles does not estimate personal net worth.
Get an email with a short summary when NRX Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get NRXP alertsStephen Willard is recorded as CEO at NRX Pharmaceuticals, Inc. (NRXP) since July 12, 2022. NRX Pharmaceuticals, Inc. reported in an 8-K filed October 11, 2024 that Stephen Willard resigned as Chief Executive Officer, effective October 7, 2024. NRX Pharmaceuticals, Inc. reported in an 8-K filed July 15, 2022 that Stephen Willard was appointed member of the Board of Directors, effective July 12, 2022. NRX Pharmaceuticals, Inc. reported in an 8-K filed July 15, 2022 that Stephen Willard was appointed Chief Executive Officer ("CEO"), effective July 12, 2022. The proxy statement of NRX Pharmaceuticals, Inc. reports total compensation of $799,871 for Stephen Willard in fiscal 2022, including a base salary of $233,871. Stephen Willard has spoken on 8 earnings calls across 1 company, most recently for NRX Pharmaceuticals, Inc. on August 15, 2024. NRX Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at NRX Pharmaceuticals, Inc. includes Jonathan C. Javitt (CEO, Chairman and Board Member), Jonathan Javitt (CEO and Chairman), Bennett Kim (CFO and Board Member) and 7 others.
“On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “Company”) provided notice to the Board that he was resigning from the Company, effective immediately, in order to assume the leadership of an early stage biotechnology company.”
“On July 12, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the "Company") appointed Stephen Willard, 61, to serve as Chief Executive Officer ("CEO") of the Company and a member of the Board of Directors, with immediate effect.”
“Jonathan, thank you for those very gracious comments. The chance to lead NRx has been one of the great joys of my life and I look forward to helping guide NRx to its success as a commercial enterprise.”
“NRx has had an incredibly productive and eventful start to 2024, with a great deal more to come through the remainder of the year. We are accelerating our work to bring hope to life.”
“As you know, I joined NRx as CEO in July 2022. My job was to reduce a daunting cash burn and help align the management team into a dedicated group that has the potential to take our drugs to market.”
“The third quarter represents a potential turning point for our company as we are approaching our clinical trial enrollment goals for our partnered foundation product, NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression.”
“We scheduled this conference call to coincide with World Bipolar Day. As you know, bipolar depression is a lethal condition that affects 2% of Americans, nearly 7 million people, and a similar percentage of the world's population.”
2022-07-12–present
Start not stated–2024-09-05
Last confirmed by a filing; no departure on record
Start not stated–2024-10-07
Biotechnology · Healthcare
CEO
2022-07-12–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | NRX Pharmaceuticals, Inc. (NRXP) | Chief Executive Officer | $233,871 | $799,871 |
